Mark Gilreath Net Worth: Verified Estimate and How It’s Calculated

The most credible estimate for Mark Gilreath's net worth as of May 2026 is approximately $6.2 million, based on reported share holdings in ECPM Holdings, LLC as recalculated by Benzinga in September 2024. That figure is specifically tied to his equity stake in the healthcare business he built, not to broader undisclosed assets, so treat it as a floor rather than a ceiling.

Who is Mark Gilreath, and could this be someone else?

Mark Gilreath is a healthcare executive and private equity operating partner best known for founding and leading United Digestive, a gastroenterology physician practice management company based in Atlanta, Georgia. He served as CEO from when he facilitated the company's formation in 2018 through 2023, when Dr. Neal C. Patel was announced as his successor. Before United Digestive, Gilreath was CEO of EndoChoice, a medical device and technology company that went public in a roughly $100 million IPO covered by Forbes in September 2015. His professional background also includes a role as Operating Partner at Frazier Healthcare Partners, a major healthcare-focused private equity firm.

This is not a celebrity Mark or a sports figure, so if you landed here expecting an actor or athlete, you may be thinking of someone else. The name is also occasionally confused with similarly spelled names in the healthcare sector, but there is only one well-documented public figure matching this exact combination of name, industry, and financial data. For reference, this site also tracks figures like Mark Gilbert and Mark Biggins, who operate in entirely different industries and financial brackets. If you were specifically searching for Mark Biggins net worth, that would be a different person, since this article is about Mark Gilreath. For context, some listings use the name Mark Gilbert and can blur different net worth estimates, so it helps to confirm the exact person you mean. Gilreath sits squarely in the healthcare business world.

What "net worth" actually means here

Net worth is total assets minus total liabilities. Simple in theory, messy in practice. For a private individual like Gilreath who has never had his personal finances publicly audited, any estimate you see is built from visible data points: stock or equity disclosures filed with the SEC, known compensation, and any public records. It does not include undisclosed real estate, private investments, savings, or debt. So when Benzinga quotes $6.21 million, that number reflects only what is traceable through SEC-required filings, specifically his reported stake in ECPM Holdings, LLC. His actual net worth could be higher, possibly significantly so, if he holds other assets that have never surfaced in public documents.

The best estimate we have, and how confident to be in it

Benzinga reported Mark Gilreath's net worth at $6.21 million, recalculated as of September 9, 2024, based on his reported shares in ECPM Holdings, LLC. That is the only numerically specific, sourced estimate available as of May 2026. No broader wealth aggregators like Forbes, CelebNetWorth, or CNBC have published a standalone profile for him, which is typical for healthcare executives who have not crossed into mainstream celebrity coverage.

Confidence level: moderate to low for the full picture, but relatively high for that specific equity component. The $6.21 million figure is derived from SEC-disclosed share data, which is verifiable. What drags confidence down is everything the number leaves out: his EndoChoice IPO exit proceeds, any carried interest from Frazier Healthcare Partners deals, compensation from his years as CEO of both EndoChoice and United Digestive, and any real estate or private investments. A realistic total net worth range is probably $6 million to $20 million or more, but that upper bound is genuinely uncertain.

How he built his wealth: the career timeline

Gilreath's financial story is a classic healthcare entrepreneur arc: build a company, take it public or sell it, then roll the expertise into the next venture, ideally backed by institutional private equity money.

1. EndoChoice CEO era (pre-2015 through sale): Gilreath led EndoChoice, a gastrointestinal medical device company, to a roughly $100 million IPO in 2015. SEC documents from the EndoChoice period show his 2016 bonus target was $209,200, giving a data point on his executive comp. The company was ultimately sold, and Gilreath's exit from that role is referenced in Natus Medical proxy materials from June 2018, which describe him as CEO of a company sold slightly more than a year prior.
2. Operating Partner at Frazier Healthcare Partners (2017-2018 overlap): Before launching United Digestive, Gilreath joined Frazier Healthcare Partners as an Operating Partner. This role typically comes with carried interest, meaning a percentage of the profits generated when Frazier's portfolio companies are sold. Carried interest at major PE firms can add millions to a partner's net worth over a fund's lifecycle, though these figures are rarely disclosed.
3. United Digestive CEO (2018-2023): He facilitated the formation of United Digestive in 2018 and served as CEO through 2023. The company grew into a multi-site gastroenterology practice management organization, and during his tenure it completed a private equity partner swap, which is a meaningful financial event for equity holders. His January 2021 interview on the United Digestive site documents his leadership during this growth phase.
4. Post-CEO phase: After Dr. Patel assumed the CEO role in 2023, Gilreath's current role is less publicly documented. His LinkedIn profile references Founders Fuel and board-level affiliations, suggesting continued involvement in healthcare ventures.

Assets, investments, and what's actually public

Here is an honest split of what is known versus unknown for Gilreath's asset picture:

The honest answer is that the public record on Gilreath's asset base is thin outside of the ECPM Holdings disclosure. That is not unusual for private healthcare executives. Unlike publicly traded company insiders who must disclose all stock transactions, PE-backed company executives operate with far less mandatory transparency.

Why you'll see different numbers on different sites

Net worth aggregator sites use wildly different methodologies, and for someone like Gilreath, the gaps are especially visible. Some sites extrapolate from salary data (using industry averages for healthcare CEO pay), some pull only from SEC filings, and some frankly just make up a round number and recycle it. The Benzinga figure is more defensible than most because it ties to a specific SEC disclosure and gives a recalculation date. A site showing $10 million or $50 million with no sourcing is almost certainly fabricating or misattributing data from a different person named Mark Gilreath entirely.

There is also a disambiguation risk. A different person with the same name, even a minor public figure, can cause estimates to bleed across profiles on aggregator sites. Always check that the net worth figure you are reading is tied to the healthcare executive background described here, not a namesake in another field.

This pattern is common across the profiles on this site. Figures like Mark Gillespie and Mark Gibbon face the same aggregator accuracy problem: a site will publish a number, other sites scrape it, and the figure spreads without anyone verifying the original source. Treat any Gilreath estimate without a clear source citation skeptically.

How to verify this yourself

If you want to do your own due diligence on Gilreath's financial standing, here is a practical checklist:

1. Search the SEC EDGAR full-text search (efts.sec.gov) for 'Mark Gilreath' to pull all filings that name him directly, including the EndoChoice proxy and ECPM Holdings documents.
2. Check Benzinga's insider trades page for Mark Gilreath to see the most recent equity disclosure recalculation and the specific share data behind the $6.21M figure.
3. Search PubMed for his published article on gastroenterology practice management to confirm his professional identity and institutional affiliations.
4. Look up United Digestive's press releases on their official site (uniteddigestive.com) to verify the CEO transition timeline and any disclosed financial milestones.
5. Check Becker's ASC (beckersasc.com) for any updated coverage of United Digestive's PE transactions, which may include indirect references to leadership equity events.
6. Search LinkedIn for Mark Gilreath and cross-reference his stated roles against the dates in SEC filings to confirm you are tracking the same individual.
7. For Georgia-based real estate, search Fulton County or surrounding county property records online, which are publicly accessible and free to search by name.

As of May 2026, the $6.21 million figure from Benzinga remains the best anchored public estimate, but it is a starting point, not a final answer. The full picture of what Gilreath earned from EndoChoice's sale, his Frazier Healthcare carried interest, and his United Digestive equity would likely push that number higher. Without those disclosures surfacing, the honest range sits between $6 million and $20-plus million, with real uncertainty at both ends.